# A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

> **NCT07012395** · PHASE2 · RECRUITING · sponsor: **Spyre Therapeutics, Inc.** · enrollment: 645 (estimated)

## Conditions studied

- Ulcerative Colitis
- Inflammatory Bowel Diseases
- Colitis
- Colitis, Ulcerative

## Interventions

- **DRUG:** SPY001
- **DRUG:** SPY002
- **DRUG:** SPY003
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07012395
- **Lead sponsor:** Spyre Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-27
- **Primary completion:** 2026-06
- **Final completion:** 2028-03
- **Target enrollment:** 645 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07012395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07012395, "A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT07012395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*